Phase II/III of Recombinant Human Serum Albumin

To Evaluate the Effectiveness of Recombinant Human Serum Albumin Versus Human Serum Albumin in Patients With Hepatic Cirrhosis and Safety of Random, Double-blind, Parallel Grouping Phase II/III Clinical Trial

This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.

Study Overview

• Status: Completed
• Conditions: Hepatic Ascites
• Intervention / Treatment: Drug: Recombinant Human Serum Albumin; Drug: Recombinant Human Serum Albumin; Drug: Human serum albumin; Drug: Human serum albumin

Detailed Description

This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.

It is divided into two phases: Phase II and Phase III. In phase II, the effect of rHSA on improving serum albumin level in cirrhotic ascites patients will be evaluated with different doses and courses of treatment, and the relationship between dose and efficacy will be determined, so as to provide basis for drug administration plan and sample size calculation of phase III study. In phase III, the efficacy of rHSA will be evaluated with the change of serum albumin concentration from baseline immediately after the completion of the last intravenous administration as the main index, and its safety, PD characteristics and immunogenicity will be further evaluated.

• Study Type: Interventional
• Enrollment (Actual): 92
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: dong Ji Jia, Ph.D; Phone Number: +010 63138339; Email: jia_jd@ccmu.edu.cn

Study Locations

• China
  • Shenzhen
    • Guangdong, Shenzhen, China, 10084
      • Shenzhen Protgen Ltd
      • Contact: jun Ya An; Phone Number: 86+13699223097; Email: anyajun@protgen.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Agreed to follow the experimental treatment plan and visit plan, voluntarily enrolled in the group, and signed the informed consent in person;
2. Age ≥18 years old and ≤70 years old, regardless of gender, on the date of signing the informed consent; Body mass index (BMI) was in the range of 18.0 to 29.0 kg/m2 (including boundary values);
3. Patients clinically diagnosed with decompensated cirrhosis with ascites of grade 1 to grade 2 and serum albumin (ALB) <30 g/L were confirmed by abdominal ultrasound examination during the screening period.
4. Fertile men and women of childbearing age (women of childbearing age include premenopausal women and women within 2 years after menopause) are willing to sign the informed consent from the time after the last administration of the investigational drug 3 Take effective contraceptive measures (condom, contraceptive sponge, contraceptive gel, contraceptive film, intrauterine device, oral or injectable contraceptive, subcutaneous implant, etc.) within a month; Pregnancy test results must be negative for women of childbearing age within 7 days or less before the initial trial drug administration.

Exclusion Criteria:

1. People who have a known history of allergy/allergic reaction to yeast or yeast-derived products, or to any component of the study preparation; Allergic constitution (multiple drug or food allergy), or have a history of biological product allergy, other causes Had a history of severe systemic anaphylaxis and was judged by the investigator to be unsuitable for treatment with the experimental drug;
2. At the time of screening, there were severe digestive diseases and complications that were deemed unsuitable for participation in this study by the investigators, including but not limited to malignant ascites and a diagnosis of Grade III or IV liver according to the West-Haven grading criteria Patients with encephalopathy, portal vein cancer thrombus/thrombus, circulatory dysfunction after abdominal puncture, obstructive biliary tract disease identified by ultrasound or other imaging, gastrointestinal bleeding who stopped bleeding less than 10 days after treatment or did not effectively stop bleeding after endoscopic ligation, or who were at greater risk of bleeding during the trial as assessed by the investigator (e.g., before screening) Gastroscopy within 3 months indicated severe esophageal and fundus varices with positive red sign);
3. At the time of screening, there was a history of active cardiovascular disease or other conditions that the investigator judged unsuitable for human albumin therapy, including, but not limited to, hypertension (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, The investigators judged that patients were well controlled and stable), severe anemia, acute heart disease, severe cardiopulmonary or structural heart disease, severe arrhythmia, decompensated heart failure (normal or high blood volume), unstable angina, and nearly 6 Myocardial infarction, medicated tachycardia/bradycardia, third-degree atrioventricular block occurred within a month;
4. Patients with active metabolic system diseases or medical history (except diabetic patients with good blood glucose control) at the time of screening, or patients with combined renal function injury who are not suitable for serum albumin treatment according to the investigators;
5. If there are serious underlying diseases during screening, the researchers think it is not suitable to participate in this study. These include, but are not limited to, active malignancies (including hepatocellular carcinoma [HCC]), pulmonary edema, bleeding prone or active bleeding diseases, uncontrolled infections (including active spontaneous bacterial peritonitis [SBP]), thyroid dysfunction (according to the National Cancer Institute Standard for Common Terminology for Adverse Events [NCI CTCAE] version 5.0 3 Grade and above), etc.;
6. The patient has the following abnormalities in laboratory examination:

(1). Liver function: alanine aminotransferase (ALT) > 5×ULN (upper limit of normal value); Aspartate aminotransferase (AST) >5×ULN; Serum bilirubin (TBIL) >4× the upper limit of normal (ULN) or was deemed unsuitable for trial participation by the investigator; (2) Renal function: serum creatinine >3× upper limit of normal (ULN), urine protein positive and deemed unfit for study; (3) Bone marrow function: absolute value of neutrophil (ANC) <1.0×10^9/L; Platelet (PLT) <20×10^9/L; Hemoglobin (HGB) <70 g/L; (4) Coagulation function: prothrombin time (PT) extended >5s; 7. Persons who have been treated with human plasma preparations (including human blood albumin preparations) within 7 days prior to the initial administration of the experimental drug; People with a history of organ transplantation; Those who need or plan to undergo interventional invasive testing or therapy during the study; 8. Those who have participated in or are participating in clinical trials of other new drugs or medical devices and have used investigational drugs/investigational treatments within 30 days prior to screening; 9. Those who test positive for antibodies to the human immunodeficiency virus (HIV); 10. Pregnant or lactating women; 11. Other reasons why the researcher considered it inappropriate to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days	Drug: Recombinant Human Serum Albumin; The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days; Drug: Recombinant Human Serum Albumin; The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
Experimental: Group 2; The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days	Drug: Recombinant Human Serum Albumin; The experimental drug (recombinant human serum albumin injection) was administered 10 g/ day for 14 days; Drug: Recombinant Human Serum Albumin; The experimental drug (recombinant human serum albumin injection) was administered 20 g/ day for 7 days
Active Comparator: Group 3; Control drug (human blood albumin injection) 10 g/ day for 14 days	Drug: Human serum albumin; Control drug (human blood albumin injection) 10 g/ day for 14 days; Drug: Human serum albumin; Control drug (human blood albumin injection) 20 g/ day for 7 days
Active Comparator: Group 4; Control drug (human blood albumin injection) 20 g/ day for 7 days	Drug: Human serum albumin; Control drug (human blood albumin injection) 10 g/ day for 14 days; Drug: Human serum albumin; Control drug (human blood albumin injection) 20 g/ day for 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in serum albumin concentration	Change in serum albumin concentration from baseline confirmed by albumin examination immediately after completion of last intravenous administration	14 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ascites depth changes	Change in ascites depth from baseline after administration	57 days
Proportion of subjects with serum albumin concentration ≥35 g/L	Proportion of subjects with serum albumin concentration ≥35 g/L confirmed by albumin examination at completion of final IV administration	14days
The time when serum albumin concentration reached ≥35 g/L	The time when serum albumin concentration reached ≥35 g/L	57 days
Abdominal circumference change	Changes in abdominal circumference from baseline after administration	57 days
Weight change	Change in body weight from baseline after administration	57 days

Collaborators and Investigators

• Sponsor: Protgen Ltd
• Investigators: Study Director: dong Ji Jia, Ph.D, Beijing Friendship Hospital

Study record dates

Study Major Dates

• Study Start (Actual): May 25, 2023
• Primary Completion (Actual): July 25, 2023
• Study Completion (Actual): September 6, 2023

Study Registration Dates

• First Submitted: May 5, 2023
• First Submitted That Met QC Criteria: May 5, 2023
• First Posted (Actual): May 15, 2023

Study Record Updates

• Last Update Posted (Actual): April 2, 2024
• Last Update Submitted That Met QC Criteria: April 1, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Ascites
• Other Study ID Numbers: rHSA 2020-3（Phase Ⅱ）

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No